






The effects of naringenin on oxidative stress parameters in cardiac 
muscles of diabetic rats. 
 
                                           By 
                          Mcobothi Esethu Nosibusiso 
                                             218007172 
                              
 
 
Submitted in partial fulfilment of the requirements for the award of the Degree of  
                                           MSc. (Med Sci.) (Pharmacology) 
College of Health Sciences  
                                                                 2019 
 
Molecular and Clinical Pharmacology Laboratory Department of Pharmacology Discipline of 
Pharmaceutical Sciences, School of Health Sciences University of KwaZulu-Natal, Westville Campus, 
Durban South Africa.  
ii 
 





MCOBOTHI ESETHU NOSIBUSISO 
 
 
      Submitted in partial fulfilment of the requirements for the award of the degree of  
      MSc. (Med Sci.) (Pharmacology) 
  
 
Department of Pharmacology, Discipline of Pharmaceutical Sciences, School of Health Sciences, 
University of KwaZulu-Natal, Westville Campus, Durban, South Africa  
 
As the candidate’s supervisor, I have approved this dissertation for submission 
Name:   






                              
DECLARATION 
 
    I, Mcobothi Esethu Nosibusiso, declare that: 
 
1. The work reported in this thesis, except where indicated is my own original work. 
2. This thesis has not been submitted for any degree or examination at any other university. 
3. This thesis does not contain other persons’ data, pictures, graphs or other information, unless 
specifically acknowledged as being sourced from other persons. 
4. This thesis does not contain other persons’ writing, unless specifically acknowledged as being 
referenced. Where other written sources have been quoted, then: 
a) their words have been re-written but the general information attributed to them has been 
referenced. 
b) where their exact words have been used, then their writing has been placed in italics, 
quotation marks and referenced. 
5. This thesis does not contain text, graphics or tables copied and pasted from the internet unless 
specifically acknowledged and the source being detailed in the reference sections. 
 
Signed:                                                                    Date: 








This study has been submitted in fulfilment of the academic requirements for obtaining a 
Masters in Medical Science (Pharmacology). The use of information from other sources in this 















                                                         
v 
 
                                                     ACKNOWLEDGEMENTS 
Given this opportunity, firstly I would like to thank God for blessing me with strength to 
complete this project and for his sufficient grace upon my life. Appreciation goes out to my 
supervisor for accepting me into his research group and allowing me to learn, grow and blossom 
into this young scientist I am today, without his guidance it wouldn’t have been possible. 
 I would also like to extend my heartfelt love and appreciation to my parents who have loved 
me, supported me, prayed for me and guided me through this journey, thank you for teaching 
me the importance of being a young and educated woman. To my siblings, my precious friends 
and loved ones thank you for your unconditional love, support, prayers and encouragement. 
 I would also like to thank my colleagues at the Pharmacology Department for creating an 
excellent working atmosphere and thank you for the assistance and advice given to me 
throughout my study.  
I also wish to appreciate the staff of the Biomedical Resource Unit (BRU) at the Westville 
Campus UKZN, for their technical assistance and expertise. 
I am thankful to the National research foundation (NRF), the College of Health Sciences at the 
University of KwaZulu-Natal and Hans Merensky Holdings for financial support throughout 















1. Presentation at UKZN College of Health Sciences Research Symposium (November 
2019), Durban, South Africa, Tittle: Naringenin ameliorates cardiac oxidative stress in 


















                                                       LIST OFABREVIATIONS 
 
ADA                                             American Diabetes Association 
AGEs                                             advanced glycation end products 
AMPK                                            Adenosine monophosphate-activated protein kinase 
ANOVA                                         Analysis of variance 
AREC                                             Animal Research Ethics committee 
AUC                                                Area under the curve 
BHT/TBA                                        Butylated hydroxytoluene /Thiobarbituric acid 
BRU                                                 Biomedical Research Unit 
CAT                                                  catalase 
CH3+                                                carbonium ion 
CHD                                                 coronary heart disease 
Cpr                                                     concentration of protein 
CRP                                                   C- reactive protein 
CVDs                                                 cardiovascular diseases 
DCM                                                 Diabetic cardiomyopathy 
DKA                                                 Diabetic ketoacidosis 
DPP-4                                               Dipeptidyl- peptide-4 inhibitors 
DTNB                                               5, 5’-dithio-bis-2-nitrobenzoic acid 
viii 
 
ELISA                                               enzyme-linked immunosorbent assay 
ERK1/2                                              Extracellular signal-regulated kinase 1/2 
FBG                                                   Fasting blood glucose 
FDA                                                   Food and drug administration 
FFAs                                                  Fast Fatty acids 
FPI                                                     Fasting plasma insulin 
G6Pase                                              Glucose-6-phosphatase 
G6PD                                                 Glucose-6-phosphate dehydrogenase 
GAPDH                                             glyceraldehyde-3-phosphate dehydrogenase 
GDM                                                  Gestational diabetes mellitus 
GLP-1                                                Glucagon- like peptide -1 agonist 
GLUT 1-5                                          Glucose transporter 1-5 
GPx                                                    Glutathione peroxidase 
GSH                                                    Reduced glutathione 
GPx                                                     Glutathione peroxidase 
GSSG                                                  Oxidised glutathione 
GTT                                                    Glucose Tolerance Test 
HbA1C                                               Haemoglobin A1c 
HDL                                                   High density lipoprotein 
HLA-DR3/DR4                                 Human leucocyte antigens 
ix 
 
HNF-1α/4α                                        Hepatocyte nuclear factor homeobox 
HOMA-IR                                         Homeostasis Model Assessment of Insulin resistance 
HRP                                                  Horseradish peroxidase 
HW                                                   Heart weight 
HW/BW                                           Heart weight/body weight 
ICA                                                  islet cell activation 
IDF                                                  International diabetes Federation 
IL-1β                                               Interleukin- 1beta 
IL-6                                                 Interleukin- 6 
INS                                                 Insulin 
IRS                                                 Insulin receptor substrate 
I-R                                                  Ischemia-reperfusion 
IR                                                   Insulin Resistance 
IV                                                   intravenous 
JNK                                               Jun nuclear kinase 
LDL                                               Low density lipoprotein 
LPL                                               Lipoprotein lipase 
LPO                                               Lipid peroxidation 
LV                                                 Left ventricle 
LVH                                               Left ventricular hypertrophy 
x 
 
LVW/BW                                       Left ventricular weight/body weight 
MAPK                                            Mitogen- Activated kinase 
MDA                                              Malondialdehyde 
MetS                                               Metabolic syndrome 
MODY 1/2/3                                  Maturity onset diabetes of the young 
NADPH/NADH/NAD+                 Nicotinamide adenine dinucleotide phosphate 
NAR                                               Naringenin 
NC                                                  Normal control 
NFkB                                            Nuclear factor kappa-light-chain enhancer of activated B cells 
PARP-1                                       poly-ADP-ribose polymerase-1 
PBS                                              phosphate buffered saline 
PEPCK                                         Phosphoenolpyruvate carboxykinase 
PKC                                             Protein kinase C 
PPAR-α                                       peroxisome proliferator activated receptor-α 
PPAR-γ                                       peroxisome proliferator activated receptor -γ 
RAAS                                         Renin- Angiotensin-Aldosterone system 
RAGE                                         Receptor for advanced glycation end products 
ROS                                            Reactive oxygen species 
SGLT2                                       Sodium glucose cotransporter 2 inhibitor 
SOD                                          Superoxide dismutase 
xi 
 
STZ                                           Streptozotocin 
T1DM                                       Type 1 diabetes mellitus 
T2DM                                       Type 2 diabetes mellitus 
TBARS                                     Thiobarbituric acid reactive substances 
TG                                             Triglycerides 
TNF-α                                       Tumor necrosis factor alpha 
TZD                                           Thiazolidinediones 
VLDL                                        Very low density lipoprotein 
WHO                                         World Health Organisation 













LIST OF FIGURES 
Chapter 1 
Figure 1. Worldwide prevalence of diabetes  
Figure 2. Microvascular and macrovascular complications resulting from different forms of 
diabetes mellitus. 
Figure 3.  Factors contributing to the development of type II diabetes mellitus.  
Figure 4 A.  Mechanism through which hyperglycaemia leads to oxidative stress, inflammation 
and cardiovascular dysfunction through activation of polyol pathway (aldose reductase 
pathway) 
Figure 4 B. Mechanism through which hyperglycaemia leads to oxidative stress, inflammation  
and cardiovascular dysfunction through the production of AGEs. 
Figure 5. Pathophysiology of diabetic cardiomyopathy.  
Figure 6. Different stages of the development of diabetic cardiomyopathy. 
Figure 7. Whole grape fruit and the structure of naringenin. 
Figure 8. Enzymatic hydrolysis of naringin to produce naringenin. 
Figure 9. Anti-diabetic mechanism of naringenin. 
Figure 10. Schematic summary of methodology.  
Chapter 3 
Figure 11. Changes in live body weights between days 0 and 57 of treatment (*, #p < 0.0001 
compared to control, ^, @ p < 0.05 compared to STZ group and &p = 0.0026 compared to STZ+ 




Figure 12. Average daily water intake per gram body weight in all treatment groups (****p < 
0.0001 compared to control group, @ p < 0.05 compared to STZ group and &p<0.05 compared 
to STZ + NAR group). 
Figure 13. Fasting blood glucose concentrations (***p <0.05 compared to control group, 
 # #, # # #p < 0.05 compared to STZ group). 
Figure 14. Glucose tolerance tests (GTT) in various treatment groups. A) Blood glucose 
concentrations vs time (GTT curves) B) Calculated AUC from the GTT plots (****p < 0.0001 
compared to control group and # p < 0.05 compared to STZ group). 
Figure 15. Fasting plasma insulin concentrations (****p < 0.05 compared to control group, @p 
< 0.05 compared to STZ group and &p < 0.05 compared to STZ+ NAR group).  
Figure 16. Homeostasis Model Assessment (HOMA) of insulin resistance in all treatment 
groups (****p < 0.0001 compared to control group, @ p < 0.05 compared to STZ group and 
&p< 0.05 compared to STZ+ NAR group). 
Figure 17. MDA concentrations were measured as an index of lipid peroxidation in all the 
treatment groups (****p < 0.05 compared to control, @p < 0.05 compared to STZ group and & 
p < 0.0001 compared to STZ+NAR group). 
Figure 18. Catalase activity in all treatment groups (#p < 0.05 compared to control group, @p 
< 0.0001 compared to STZ group and &p< 0.05 compared to STZ + NAR group). 
Figure 19. Superoxide dismutase (SOD) activity in all the treatment groups (**, # p < 0.05 
compared to control group, @p < 0.05 compared to STZ group and & p< 0.05 compared to STZ 




Figure 20. Glutathione peroxide (GPx) activity of all the treatment groups (****, #p < 0.0001 
compared to control group, @ p < 0.05 compared to STZ group and &p < 0.0001 compared to 
STZ +NAR group). 
Figure 21. Tumor necrosis factor alpha (TNF-α) activity in all treatment groups (****p < 0.05 
compared to control group, # p < 0.05 compared to STZ and &p< 0.05 compared to STZ+NAR 
group). 
Figure 22. Calculated HW: BW ratio (****p < 0.05 compared to control group, #p < 0.05 
compared to STZ group and &p < 0.05 compared to STZ+NAR group). 
Figure 23. Left ventricular weight to heart weight ratio (LVW/HW), (****p < 0.05 compared 
to control group, #p < 0.05 compared to STZ group and &p< 0.05 compared to STZ+NAR 
group). 
LIST OF TABLES 
  Chapter 1 
Table 1. Complications, risk factors & interventions in microvascular and macrovascular 
complications of diabetes.  
Table 2. Antidiabetic drugs approved by the FDA. 
Chapter 2 
Table 3. Animal treatment protocol. 






                                                             ABSTRACT 
Introduction: Diabetic cardiomyopathy (DCM) is defined by hypertrophy, oxidative stress, 
fibrosis and inflammation of the cardiac muscle. Hyperglycemia-associated oxidative stress 
plays an important role in the development of cardiac hypertrophy. Naringenin a citrus fruit-
derived flavonoid has previously been demonstrated to have antioxidant, anti-diabetic, anti-
inflammatory and cardioprotective properties by as yet unknown mechanisms. 
Aim: To investigate the effects of naringenin on oxidative stress parameters in cardiac muscles 
of diabetic rats. 
Methods:  Wister rats (250-300g) were randomly divided into six groups (n=7). Groups I and 
IV were orally treated daily for 56 days with 3.0 ml/ kg Body Weight (BW) of distilled water 
and 60 mg/kg BW of naringenin in distilled water, respectively. Groups II, III, V and VI were 
made diabetic by a single intraperitoneal injection of 60 mg/kg BW of streptozotocin (STZ) 
and similarly treated with naringenin, except group VI which was treated with insulin 2.0 
U/BW bid. Group V was pre-treated with naringenin for a period of one week before STZ 
administration. On day 57 the animals were euthanized, blood samples collected, and the hearts 
were excised, weighed and stored at -80ᴼC. Antioxidant activity (catalase, glutathione 
peroxidase and superoxide dismutase) was measured using colorimetric commercial kits. 
Malondialdehyde (MDA) levels were measured using the Thiobarbituric acid reactive 
substances assay (TBARS) while fasting plasma insulin was measured using a commercial 
enzyme-linked immunosorbent assay (ELISA) kit and insulin resistance was calculated using 
Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) and pro-inflammatory 
cytokine levels were measured by commercial ELISA kits. 
xvi 
 
Results:  Diabetic animals presented with significant (p< 0.05) weight loss, polydipsia, 
increased fasting blood glucose (FBG) levels and glucose intolerance (GI) compared to control. 
Naringenin treatment significantly increased antioxidant enzyme levels (cardiac tissue) in 
diabetic animals compared to the untreated diabetic groups. MDA and TNF-α levels (in cardiac 
tissue) were significantly increased in the untreated diabetic groups compared to the control. 
Cardiac mass to body weight ratio was increased in the untreated diabetic rats compared to the 
naringenin treated diabetic rats. 
Conclusion: Naringenin pre-treatment and naringenin post STZ treatment improved diabetic 
symptoms, antioxidant levels, heart weights and reduced inflammation suggesting its 
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CHAPTER 1: INTRODUCTION & LITERATURE REVIEW 
1.1. DIABETES MELLITUS 
1.1.1. Epidemiology of diabetes mellitus 
According to the International Diabetes Federation (IDF), 425 million people were diagnosed 
with diabetes by the year 2017 and this number is estimated to rise by 48% in 2045, where 
approximately 629 million people will be diagnosed with diabetes worldwide (International 
Diabetes Federation, Diabetic Atlas 2017; Cho et al., 2018) (Fig 1). Sedentary lifestyle, 
genetics and unhealthy food choices are the main risk factors for type 2 diabetes (World health 
organisation, 2016). Diabetic patients who develop DCM are at a higher risk of increased 











Figure 1. Worldwide prevalence of diabetes (image adapted from the International Diabetes 
Federation, Diabetic Atlas 2017). 
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1.1.2. Diabetes mellitus 
Diabetes causes microvascular and macrovascular end-point complications (Skyler et al., 2017) 
(Fig. 2). There are different types of diabetes mainly type I, type II, gestational diabetes and 
other specific types (monogenic diabetes i.e. MODY), these forms are grouped according to 
different etiologic classifications (Baynes, 2015). Although there are different classifications 
of diabetes, the underlying problem is high blood glucose levels (hyperglycaemia) 
accumulating outside the cells because of insulin defects (Baynes, 2015).  Insulin produced by 
β-cells of the islets of Langerhans in the pancreas, interacts with the insulin receptors to form 
a cascade of intracellular reactions catalysed by different enzymes. Insulin does not only 
facilitate glucose entrance into the cells but it also regulates the expression of enzymes that 
control glucose homeostasis (Guthrie and Guthrie, 2004). In the absence of insulin, the liver 
produces glucose (gluconeogenesis) to provide the cells with energy, this leads to a further rise 









Figure 2. Microvascular and macrovascular complications resulting from different forms of 
diabetes mellitus (Adapted and modified from Skyler et al., 2017). 
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1.1.3. Type I diabetes  
Type I diabetes mellitus (T1DM) can be a genetic disease resulting from autoimmune 
destruction of insulin producing pancreatic β- cells leading to progressive and irreversible 
failure of insulin secretion resulting in hyperglycaemia and a tendency to ketoacidosis (Ogbera 
et al., 2014; Kahanovitz et al.2017). There are two classes of human leucocyte antigens HLA-
DR3 and HLA-DR4 haplotypes located on chromosome number 6 which are responsible for 
insulin gene expression, responses to viral infections and regulation of T cell activation 
(DiMeglio et al., 2018). When these genes malfunction, they lead to autoimmune diseases, type 
1 diabetes included (Guthrie and Guthrie, 2004) (Paschou et al., 2018). 
Chemicals and environmental factors (viruses) can also induce type I diabetes by damaging the 
pancreatic β-cells continuously over an extended period or rapidly over a short period of time 
(Baynes, 2015). 
Streptozotocin (STZ) is an antibiotic isolated from streptomyces achromogenes known to cause 
pancreatic β-cell destruction and is widely used in experimental diabetes (Wu and Huan, 2008; 
Atkinson et al., 2015). Once taken up by the pancreatic beta cells via GLUT 2 transporters, 
STZ   induces cell death in three ways: generating free radicals, increasing nitric oxide 
production by increasing guanyl cyclase activity and DNA methylation, forming carbonium 
ion (CH3+) that activates the nuclear enzyme (poly ADP-ribose synthetase) that is part of the 
cell repair mechanism (Ventura-Sobrevilla et al., 2011; Tesch, 2007). It causes permanent 
diabetes in animal models by damaging pancreatic β-cells through generation of superoxide 
anions that act on the mitochondria causing an increase in the activity of the enzyme xanthine 
oxidase resulting in complete or partial destruction of the pancreatic β-cells (Atkinson et 
al.,2015). STZ administered in small doses to induce diabetes and administered in one large 
single dose to cause a complete necrosis of the pancreatic β-cells (Wu and Huan, 2008). Rats 
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are usually administered 45-60 mg/kg body weight of STZ to induce T1DM (Wang-Fischer 
and Garyantes, 2018). 
Diabetic animals have increased malondialdehyde (MDA) levels but decreased endogenous 
antioxidant enzyme levels (glutathione peroxidase, catalase and superoxide dismutase) when 
compared with control animals in experiments (Wang-Fischer and Garyantes, 2018). The 
decrease in antioxidant activities and simultaneous increases in MDA activities, indicates 
increased oxidative stress (Eleazu et al., 2013). Metabolism of STZ results in the degradation 
of ATP by xanthine oxidase producing uric acid as the final product this reaction generates 
ROS such as superoxide and hydroxyl radicals emanating from H2O2 dismutation during 
hypoxanthine metabolism, accelerating the process of pancreatic beta cell destruction (Eleazu 
et al., 2013; Wang-Fischer and Garyantes, 2018). 
T1DM is managed by daily injection of insulins such as rapid-acting, short-acting, immediate-
acting, long-acting and pre-mixed (IDF, 2017). 
 
1.1.4. Type II diabetes 
Type II diabetes mellitus (T2 DM) is characterised by impaired insulin secretion caused by the 
dysfunction of pancreatic β-cells or impaired insulin action through insulin resistance 
(Ozougwa et al., 2013). There are many factors that cause insulin resistance (IR) including 
obesity, sedentary lifestyle, unhealthy dietary intake, age and genetic disorders (Baynes, 2015) 
(Fig 3). 
IR is the initial defect in T2 DM as it can manifest long before any clinical symptoms can be 
detected and long before blood glucose levels are high enough to make a clinical diagnosis 
(Taylor, 1994; Guthrie and Guthrie, 2004). Insulin resistance occurs in the skeletal muscles 
and fat cells (peripheral tissues). IR can occur due to environmental factors (e.g. aging and 
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obesity) and genetic mutations in the insulin receptors (IRS) and GLUT 1-5, whereby insulin 
cannot bind to the receptors to activate the required reactions for glucose uptake (Chan et al., 
1994; Skyler et al., 2017).  
Defects in translocation of GLUT-4 protein is caused by reduced tyrosine phosphorylation of 
IRS-1 (Colditz et al., 1995). Phosphorylated IRS proteins serves as multisite binding proteins 
for various effector molecules that have Src homology 2 (SH2) domains, including 
phosphatidylinositol-3-kinase (PI3K) regulatory subunits, tyrosine kinases and growth factor 
receptor binding proteins (Wagner et al., 2013). IRS proteins work as essential signaling 
intermediates of activated cell surface insulin receptors and play an important role in 
maintaining basic insulin-mediated cellular functions including fatty acid synthesis, glycogen 
synthesis, cell survival through glucose uptake, protein synthesis and inhibit gluconeogenesis 
(Albegali et al., 2019) 
 IR occurs at multiple levels in cells, from the cell surface to the nucleus including insulin 
receptor desensitization. Inhibition of IRS-1 and insulin receptor substrate-2 (IRS-2) results in 
the suppression of IRS protein functioning and inhibition of PI3K signaling. Insulin stimulates 
amino acid uptake, inhibits protein degradation and promotes protein synthesis and a shortage 
in the diabetic state causes an increase in protein catabolism, rather than a decline in protein 
synthesis (Colditz et al., 1995). 
In the development of IR, insulin production increases in the pancreatic β-cells to maintain 
homeostasis of blood glucose levels for normal bodily functions (Chan et al., 1994). If IR 
increases or persists over an extended period, the β-cells undergo genetic changes or exhaustion 
(Taylor et al., 1994; Van der Zijl et al., 2011). This causes decrease in insulin secretion and 
continuation of IR resulting in the rise of blood glucose levels favouring the development of 
T2 DM (Guthrie and Guthrie, 2004). The Homeostatic Model Assessment of Insulin Resistance 
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1.1.5. Other forms of Diabetes Mellitus  
Some forms of diabetes are more common than others, gestational diabetes (GDM) is defined 
as glucose intolerance with onset of pregnancy and it has become one of the global health 
concerns in pregnant women, GDM is diagnosed in the second or third trimester of pregnancy 
(Mishra et al., 2018). Overweight women, women who have had GDM before or have a family 
history of diabetes are at an increased risk of developing gestational diabetes. GDM left 
untreated can result in problems with the fetus such as respiratory problems and low blood 
sugar levels.  
GDM is associated with increased risks of maternal and fetal complications (Nien et al.,2007; 
Morampudi et al., 2017). Fetal macrosomia is a common complication of diabetes in pregnancy 
it is caused by fetal hyperinsulinemia that occurs as a physiological response to maternal 
hyperglycemia. Women pregnant with macrosomic fetuses are at increased risk of 
preeclampsia, labor abnormalities, severe perineal lacerations, risks of preterm birth and 
cesarean section. The fetus is at risk of stillbirth, intracranial hemorrhage, shoulder dystocia 
and malformations (Nien et al., 2007). The new born baby is at risk of developing 
hyperbilirubinemia, hypocalcemia, hypoglycemia, hypomagnesemia, polycythemia vera and 
neonatal cardiomyopathy (Morampudi et al., 2017). Later in life, the baby may be at an 
increased risk for obesity and T2DM (Mishra et al., 2018).   
Maturity Onset Diabetes of the Young (MODY) is a rare form of diabetes linked with family 
history (Gerber et al., 2003). It is inherited in the form of an autosomal dominant trait, which 
is normally a result of mutations in the glucokinase gene on chromosome 7p; glucokinase is 
the main enzyme of glucose metabolism in the pancreas and the liver (Baynes, 2015). MODY 
is characterized by a slow onset of symptoms, the absence of obesity, lack of ketosis, and no 
evidence of β-cells autoimmunity (Ozougwu et al., 2013). There are five different forms of 
MODY.  MODY 1, MODY 3 and MODY 5 are caused by mutations in the hepatocyte nuclear 
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transcription (HNF) 4α, HNF-1α and HNF-1β factors respectively. These transcription factors 
are expressed in the liver but also in other tissues including the pancreatic islets and the kidney. 
They affect islet development or the expression of genes important in glucose-stimulated 
insulin secretion and the maintenance of β-cells mass (Baynes, 2015).   
Individuals with MODY 2 have mutations in the glucokinase gene that plays a key role in 
glucose metabolism and insulin secretion and MODY 4 is a rare variant form caused by 
mutations in insulin promoter factor (IPF) 1, which is a transcription factor that regulates 
pancreatic development and insulin gene transcription together with other genes involved in 
glucose metabolism (Gerber et al., 2003). 
 
1.1.6. Complications associated with diabetes 
There are various complications resulting from T1 and T2 DM affecting various parts of the 
body, these complications can be microvascular complications (small vascular injury) affecting 
the retina, kidneys and nerves and macrovascular complications (injury to large blood vessels) 
affecting the heart, brain and veins (Barret et al., 2017) (Table 1). The mechanisms by which 
some of these complications develop is similar to that of people who do not have diabetes but 
diabetic patients have accelerated development due to specific risk factors (Guthrie and 







Table 1. Complications, risk factors & interventions in Microvascular and macrovascular 
complications of diabetes.  
 
                                                                     MICROVASCULAR 
 
 Risk Factors Screening Methods Therapeutic Interventions  
Retinopathy ➢ Hyperglycaemia 
➢ Hypertension 
➢ Dyslipidemia 
➢ Oxidative stress 
 
➢ Fundal photography 
➢ Ophthalmoscopy 
 
➢ Improved glycaemic 
control 













➢ Improved glycaemic 
control 







➢ Oxidative stress 
 
➢ History & physical 
examination 
 
➢ Improved glycaemic 
control 
 













➢ Oxidative stress 
 
➢ Lipid profile every 
5 years 
➢ Blood pressure 
➢ Echocardiology 
➢ Tissue doppler 
imaging (TDI) 
➢ Magnetic resonance 
imaging (MRI) 
➢ Nuclear Imaging  
 
➢ Improved glycaemic 
control 




1.1.7. Diagnosis, management and current treatment for diabetes mellitus 
Blood glucose criteria is used to diagnose diabetes either by fasting blood glucose levels (FBG) 
(normal 5.6 mmol/L), (prediabetes 5.6-6.9 mmol/L) and (diabetes ≥7.0 mmol/L) or random 
blood glucose levels (normal <11.1 mmol/L) and (diabetes ≥11.1 mmol/L) or the 2 hours blood 
glucose (2h-BG) value after 75 g oral glucose tolerance test (OGTT) whereby (normal <5.6 
mmol/L),(prediabetes 7.8-11.0 mmol/L) and (diabetes ≥ 11.1 mmol/L) (American Diabetes 
Association, 2018). There are various medications approved by the FDA used in the 





























 SIDE EFFECTS 
 
Biguanides 
➢ Metformin ➢ Reduces insulin resistance. 









➢ Exenatide  
  
➢ Increases secretion of insulin 
from the pancreas, delays 
gastric emptying. 










➢ Decreases digestion and 






(TZD) (PPAR γ -
Agonist) 
➢ Pioglitazone  
➢ Rosiglitazone  
 
➢ Increase insulin sensitivity of 
the body cells  
➢ Reduces gluconeogenesis in 
the liver. 




increased risk of 
bladder cancer and 
increased risk of non-
fatal heart attack  
 
Sulfonylureas 




➢ Insulin secretagogues.  Hypoglycaemia (low 
blood sugar) 
Meglitinides ➢ Repaglinide 
➢ Nateglinide 
 
➢ Stimulate the pancreas to 










➢ Increases secretion of insulin 
by the pancreas. 
➢ Decreases glucagon release 
after meals. 
➢ Block the degradation of 













➢ Inhibits glucose re-
absorption in the glomerulus 
leading to glycosuria.  
 
Genital and urinary 
infections, frequent 





1.2   OXIDATIVE STRESS & HYPERGLYCEMIA 
1.2.1 Hyperglycemia induced oxidative stress 
Oxidative stress is defined as an imbalance between ROS production and antioxidant defence 
mechanisms (Shin et al., 2001; Stykal et al., 2017; Poljšak and Fink, 2014). ROS have the 
ability to damage DNA, lipids and other biomolecules in the body. They can also accelerate 
the development of diseases such as cardiovascular diseases, cancer and diabetes (Valko et al., 
2007).  In diabetes, free radicals are produced from uncontrolled hyperglycaemia through a 
number of mechanisms such as the initiation of the polyol pathway, autoxidation of glucose 
and enhanced formation of intracellular Advanced- Glycation- End -Products (AGEs) (Giacco 
and Brownlee 2010). Weight loss, polydipsia, polyuria blurred vision are some of the 
symptoms associated with diabetes (ADA, 2016). 
 
1.2.2 The Polyol pathway 
This polyol pathway is a major contributor of hyperglycaemia-induced oxidative stress, 
because about 30% of glucose enters this pathway (Cheng and González, 1986) (Fig. 4A).  
Activation of the aldose reductase pathway increases the rate of NADH/NAD+ altering the 
redox potential therefore increasing levels of superoxide ions and decreasing nitric oxide (NO) 
levels leading to oxidative stress that later results in endothelial dysfunction, 
hypercoagulability and inflammation implicated in cardiovascular dysfunction (Koya et. al., 
1998). This initially starts by a conversion of NAD+ to NADH by sorbitol dehydrogenase 
increasing the concentration of NADH which is a substrate for NADH oxidase which can 
produce large amounts of superoxide radicals in the presence of oxygen and other related 
oxidant species (Griendling et. al 2000) (Fig. 4A). If these superoxide radicals are produced in 
large amounts, they can form peroxynitrite when they react with NO, thereby causing a decline 
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in nitric oxide levels (Beckman and Koppenol, 1996; Pacher et al., 2007). NO levels play a 
role in the formation of other oxidants, if levels of NO are normal other oxidants will not be 
formed (Fig. 4 A). The rise in glucose results in an increased level of fructose, this excess 
glucose is transferred into sorbitol by aldose reductase using NADPH as a cofactor. Sorbitol 
dehydrogenase oxidizes sorbitol to form fructose and produce NADH.  The increase in fructose 
concentrations can activate protein kinase C (PKC) whereby glyceraldehyde-3-phosphate 
dehydrogenase is inhibited by poly (ADP-ribose) polymerase due to increased ratio of 
NADH/NAD+, this then favours the production of diacylgycerol which initiates PKC activation 
(Du et. al., 2003) (Fig. 4 A). PKC participates in redox imbalance thereby causing oxidative 
stress and a decrease in NO resulting in an inflammatory response causing endothelial 





Figure 4 A.  Mechanism by which hyperglycaemia leads to oxidative stress, inflammation and 
cardiovascular dysfunction through activation of polyol pathway (aldose reductase pathway) 
(Adapted and modified from Domingueti et al., 2016). 
 
1.2.3 Autoxidation & Protein glycation 
Elevated levels of glucose (hyperglycaemia) lead to the increased production of products such 
as hydroxyl radicals, hydrogen peroxide, and superoxide (Wolff and Dean 1987) (Fig. 4 B). 
All these products bind and damage proteins and lipids by fragmentation as they accelerate the 
formation AGEs (Baynes, 1991; Zhao, 2001) (Fig. 4 B). Protein glycation is a non-enzymatic 
reaction in glucose and amino acid groups of proteins increasing the production of ROS leading 
to oxidative stress and decreased NO resulting into endothelial dysfunction, hypercoagulability 
and inflammation (Aroson and Rayfeild, 2002) (Fig. 4 B). ROS are also are produced when the 
AGEs interact/bind with their cell receptors RAGEs (Creager et al., 2006) (Fig. 4 B). AGEs 
produced in this way cause cellular damage by several mechanisms, proteins changed by these 
precursors attach to the AGE receptors and cause glucotoxicity in cells like endothelial cells, 
monocots/macrophages (Wright et al., 2006). Once these intracellular ROS are generated, it 
further activates the nuclear factor-ҡB (NF-kB) that increases the production of pro-
inflammatory cytokines and pro-coagulant molecules resulting into endothelial dysfunction 












Figure 4 B. Mechanism by which hyperglycaemia leads to oxidative stress, inflammation  
and cardiovascular dysfunction through the production of AGEs (Adapted and modified from 
Domingueti et al., 2016). 
 
1.3 DIABETIC CARDIOMYOPATHY, INFLAMMATION & SIGNALLING 
PATHWAYS 
1.3.1 Diabetic cardiomyopathy 
Diabetes increases the risk of developing cardiovascular diseases (CVDs) such as DCM, 
diabetic dyslipidaemia, coronary artery disease, ischemia and heart failure (Jia et al., 2018). It 
has been recorded that approximately 18 million diabetic patients die from CVDs every year 
(Danaei et al., 2013). DCM affects the myocardium and is characterised by myocardial fibrosis, 
dysfunctional remodelling, hypertrophy and cardiac stiffness (Jia et al., 2018). DCM is one of 
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the major cardiac complications in diabetic patients resulting from hyperglycaemia-induced 
oxidative stress, causing cardiac diastolic dysfunction and systolic dysfunction, later leading to 
heart failure (Jia et al., 2018; Beran and Yudkin, 2010). High levels of ROS lead to oxidative 
damage by interacting with lipids and proteins within the myocardium thus affecting the 
functioning, growth and repairing abilities of cardiomyocytes (Beran and Yudkin, 2010).  
 
1.3.2 Pathophysiology of diabetic cardiomyopathy 
Hyperglycemia, fatty acids and IR activate multitude cellular mechanisms in the myocardium 
and when the cardiomyocytes fail to assimilate glucose it is converted into AGEs, hexosamine 
and polyols which activate pro-inflammatory and pro-oxidant responses (Milwidsky et al., 
2015) (Fig. 5). As a compensatory mechanism fatty acid transporter are increased since ATP 
generation relies on fatty acid degradation. The free fatty acids (FFA) are taken up in large 
amounts and some saturate β-oxidation and accumulate in the cytosol as toxic secondary 
metabolites such as ceramides, diglycerides (DAG) and ROS (Lorenzo-Almoros et al., 2017) 
(Fig. 5). Lipo/gluco-toxicity and lack of ATP production promote calcium imbalance between 
the sarcoplasmic reticulum and cytosol, reducing actin-myosin complexes, triggering chronic 
inflammation, fibrosis and contractile dysfunction. FFA also bind to the Peroxisome 
Proliferator- Activated receptors (PPAR) to upregulate mitochondrial beta-oxidation enzymes 
which produce ROS and non-efficient ATP, triggering apoptosis and mitochondrial 
dysfunction (Bugger et al., 2014). All these stimuli promote the expression of miRNAs, pro- 
fibrotic and pro-hypertrophic factors which may have paracrine and autocrine effects on the 






Figure 5.  Pathophysiology of diabetic cardiomyopathy (Lorenzo-Almoros et al., 2017). (UR 
Unspecific receptors, TLRs Troll like receptors, IGFBP-7 Insulin-like growth factor binding 
protein-7, TGFβ Transforming growth factor beta, IGF-1 Insulin growth factor -1, TnI 
Troponin I/T, CT-1 Cardiotropin-1, ANP Atrial natriuretic, BNP Brain natriuretic peptide) 
1.3.3 Developmental stages of diabetic cardiomyopathy 
DCM occurs through progressive metabolic disturbances. In the early stages, structural and 
functional defects are apparent (Fang et al., 2004). DCM is clinically asymptotic in its early 
stages due to hyperglycaemia which increases the levels of antioxidants in the heart muscle as 
a compensatory mechanism (Boudina and Abel, 2010). The early stages of DCM are 
characterised by increased stiffness and Left Ventricular (LV) diastolic pressure. The 
18 
 
underlying pathological factors include cardiac insulin resistance, increased FFA levels, 
inflammation, imbalanced calcium levels and oxidative stress (Jia et al., 2018) (Fig. 6). 
The later stages of DCM show visible symptoms and antioxidant depletion leaving the 
myocardium exposed to free radicals (Gilica et al., 2017; Boudina and Abel, 2010). The 
complications in the later stages of DCM include left ventricular hypertrophy (LVH), impaired 
diastolic filling, arterial filling and relaxation, cardiac remodelling and fibrosis and as the DCM 




Figure 6. Different stages of the development of diabetic cardiomyopathy (Fang et al., 2004). 
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1.3.4 Other diabetes associated cardiovascular complications 
1.3.4.1 Diabetic dyslipidaemia 
Hyperglycaemia and defects in insulin action result in changes in plasma lipoproteins in 
diabetic patients, leading to increased risk of developing DCM compared to non-diabetic 
individuals (Adiels et al., 2008). High density lipoproteins (HDL) assists the body in the 
removal of excess cholesterol preventing atherosclerosis development (Wang et al., 2018). 
Whereas low density lipoproteins (LDL) favours the build-up of cholesterol resulting into the 
clogging of arteries causing atherosclerosis (Basta et al.,2004).  Dyslipidaemia is defined by 
overproduction of very low-density lipoprotein (VLDL) particles, lower levels of HDL and 
higher levels of LDL and triglycerides (TG) (Mulvihill et al., 2009; Schofield et al., 2016).  
 
1.3.4.2 Atherosclerosis and Coronary heart disease 
Type 1 & Type 2 diabetes both lead to the development of coronary heart disease, stroke, 
microvascular disease and accelerated atherosclerosis which have become the main cause of 
morbidity and mortality in diabetic patients worldwide (Basta et al., 2004). Atherosclerosis 
affects the functioning of multiple arteries in the body such as coronary arteries, brain arteries, 
renal arteries and carotid arteries (Orhan et al., 2015; Wang et al., 2018). Atherosclerosis is a 
chronic inflammatory condition in the blood vessels resulting in the formation of atheromatous 
plaques in the endothelial lining within the blood vessels causing stiffness and dysfunction of 
the endothelial cell lining (Chowdhury et al., 2010; Ali et al., 2010). Hypercholesterolemia is 
considered as one of the major contributors to atherosclerosis, by causing damages to the 
permeability of the endothelium which allows migration of lipids, such as LDL particles 
(Biddinger et al., 2008; Bergheanu et al., 2017). Atherogenic dyslipidaemia is one of the major 
causes of coronary atherosclerosis and coronary heart disease (CHD) and is characterised by 
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increased plasma concentrations of TG, very low density lipoproteins (VLDL), cholesterol –
rich LDL and low levels of high density lipoproteins (Mulvihill et al., 2010). 
1.3.4.3 Ischemia and Heart failure 
Hypertension, diabetes and hypercholesterolemia increase the risk of ischemia-reperfusion (I-
R) injury and heart failure (Collard and Gelman, 2001). Myocardial ischemia is caused by 
reduced blood flow to the coronary arteries, due to atherosclerosis (Han et al., 2009). The 
narrowing of blood vessels or plaque build-up cause insufficient flow of blood resulting in 
decreased cellular oxidative phosphorylation leading to failure in producing ATP and 
phosphocreatine (Bai et al., 2014) (Aziz and Yadaz, 2016). This affects the functioning of the 
ionic pump allowing calcium, sodium and water uptake, this cellular oxidative imbalance 
causes accumulation of ROS (Crossman, 2004) (Kara et al., 2014). 
 
1.3.5 Inflammation associated with diabetes 
Inflammation is characterized by swelling, redness and warmth in response to metabolic 
disturbances (Scott et al., 2004). The most dominant pro-inflammatory mediators responsible 
for initiating inflammation in various organs in the body include tumour necrosis factor (TNF-
α), interleukin-1beta (IL-1β), interleukin-6 (IL-6) and other pro-inflammatory cytokines and 
chemokines (Akash et al., 2018).  
Diabetes and hyperglycaemia alter plasma concentrations of pro-inflammatory markers 
following oxidative stress (Hansen et al., 2010; Brownlee, 2005). Diabetes leads to increased 
production of a non-specific C-reactive protein (CRP) (Fröhlich et al., 2000). Its production by 
the liver is increased during inflammation or acute infection, and it has been suggested that 
type II diabetes causes acute inflammation where there is increased release of adipokines 
(Schultz and Arnold, 1990; Pickup and Crook, 1998). Increased interlukin 6 and CRP 
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sometimes predict diabetic complications (Su et al., 2011). Increase in these cytokines 
especially TNF- α does not only affect insulin action but may also cause beta-cell failure 
(Moreli et al., 2015; Domingueti et al., 2016).  
1.4 PHARMALOGICAL EFFECTS OF NARINGENIN 
1.4.1 Medicinal plants vs Modern medicines 
Medicinal plants have bioactive compounds which can be extracted from morphological parts 
and used as medicinal agents. Medicinal plants play a vital role in ethnopharmacological health 
systems all over the world (Hosseinzadeh et al., 2015). They are considered as rich sources of 
ingredients that can be used in the development and production of drugs. They serve as 
reservoirs for bioactive compounds that are vital to human health (Mosa et al., 2015). Herbal 
medications can be suitable alternatives in combination with other fractional replacements for 
conventional medicines (Zhao et al., 2015). 
According to World Health Organisation, about 80% of the world’s population is using 
medicinal plants and currently there is increased interest in the discovery of plant-derived 
antidiabetic drugs especially in Africa (Piero et al., 2012). Herbal treatments are used mostly 
in developing countries since they are cheaper (Wadkar et al., 2008). Galega officinalis L. 
(Fabaceae) (also called French lilac) was the first medicinal plant to be described with clear 
antidiabetic properties, the plant has been used to treat diabetes ever since the Middle Ages and 
synthetic products made from this plant include metformin (Bedekar et al., 2010). 
 
1.4.2 Naringenin 
Phenolic compounds and flavonoids are known as secondary metabolites of plants, they have 
an aromatic ring consisting of at least one hydroxyl group (Tungmunnithum et al., 2018). Over 
8000 phenolic compounds occur naturally as substances from plants and a majority of these 
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compounds are classified as flavonoids occurring as aglycone, glycosides and methylated 
derivatives (Yao et al., 2004). Flavonoids are commonly found in vegetables and fruits they 
are characterized by a benzo-y-pyrone structure and vary in the structure of heterocyclic 
oxygen ring but all have the same C6-C3-C6   carbon skeleton (Corradini et al., 2011) (Fig. 7). 
 
 
Figure 7. Whole grape fruit and the structure of naringenin (Corradini et al., 2011).                                  
Flavonoids include flavones, flavanones, flavonols, isoflavones, anthocyanidins, and flavanols. 
They are regarded as potent antioxidants, free radical scavengers, metal chelators and inhibitors 
of lipid peroxidation (Ramprasath et al., 2014; Cook and Samman, 1996). By scavenging ROS, 
flavonoids limit the perpetuation of oxidative stress and prevent the formation of ROS (Cavia- 
Saiz et al., 2010). Naringenin (4, 5, 7-trihydroxyflavonon) is a flavonoid abundant in citrus 
fruits, and the skin of tomatoes (Fig.7).  
Naringenin is an aglycone of naringin following hydrolysis by naringinase. Naringin is 
hydrolyzed by α-L-rhamnosidase of naringinase to rhamnose and prunin, the prunin formed is 








Figure 8. Enzymatic hydrolysis of naringin to produce naringenin (Thomas et al., 1958, 
Ribeiro et al., 2008) 
Naringenin possess pharmacological effects such as anti-hypersensitive, hypolipidemic, anti- 
diabetic, anti-fibrotic, hepatoprotective and cardioprotective properties (Ramprasath et al., 
2014) (Fig. 9). Naringenin increases the expression of PPAR-γ and promotes peripheral 
glucose uptake by increasing GLUT-4 translocation (Mahmoud and Hussein, 2016) (Fig. 9).  
As a result, naringenin as a dietary supplement could mitigate hyperglycemia-induced 






Figure 9.  Anti-diabetic mechanism of naringenin (Mahmoud and Hussein, 2016). (NO Nitric 
oxide, GSH-GPx Glutathione peroxidase, SOD Superoxide dismutase, LPO Lipid 









1.5 HYPOTHESIS, AIM & OBJECTIVES 
1.5.1  Hypothesis 
Rats with STZ induced diabetes treated with naringenin experience less cardiac oxidative stress 
than untreated rats.  
 
1.5.2  Aim 




• To determine the effect of naringenin on the different biochemical (enzymes) and 
biological (cytokines) parameters that help to explain the oxidative stress that leads to 
cardiomyopathy. 
• To compare the effect of naringenin on heart/body weight ratio and left ventricular 








CHAPTER 2: MATERIALS & METHODS 
2.1 EXPERIMENTAL  
2.1.1    Materials and methods 
All the Enzyme Linked Immuno-Sorbent Assay (ELISA) and colorimetric assay kits were 
purchased from Biocom Africa Diagnostics, South Africa (SA). Unless otherwise stated, all 
the chemicals and reagents were purchased from Sigma Aldrich TM SA. The glucometer, 
glucometer test strips and insulin were purchased at the local pharmacy, Durban, SA. 
2.1.2  Reagents and chemicals 
➢ Sodium citrate dehydrate  
➢ pH meter (Crison Basic 20, pH-meter, crison instruments, SA) 
➢ Sodium chloride  
➢ DiSodium hydrogen phosphate  
➢ Glucometer and glucometer strips (OneTouch Select®; Lifescan Inc., Milpitas, 
California, USA) 
➢ EZ 400 Microplate Reader (Biochrom® Ltd, Cambridge, UK) 
➢ Z383k Hermle centrifuge (Labortechnik, Germany) 
2.1.2.1 Naringenin preparation 
Commercial powdered naringenin extract (3.0 g) was dissolved in 100 ml of distilled water due 
to its poor solubility it formed a suspension. 
2.1.2.2 Preparation of citrate buffer (0.1 M, pH 4.5) solution  
Citric acid crystals (1.92 g) and sodium citrate dehydrate (2.94 g) were dissolved in 100 ml of 
distilled water.  
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After these two separate solutions were prepared, they were mixed together and the pH was 
adjusted to 4.5 pH. 
2.1.2.3 Preparation of streptozotocin solution 
STZ (504 mg) was dissolved in 28 ml of citrate buffer (18 mg/ml) and administered at 60 mg/kg 
BW to the rats. 
2.1.2.4 Preparation of normal saline (0.9 % NaCl) solution  
 Sodium chloride (0.9 g) was dissolved in 100 ml of distilled water. 
2.1.2.5 Preparation of D-glucose 
This solution was prepared by dissolving (18.75 g) of D-glucose anhydrous in 50 ml normal 
saline (0.38 g/ml). 
2.1.2.6 Preparation of phosphate buffered saline (PBS) 
This solution was prepared by dissolving (8.0 g) sodium chloride, (200 mg) of potassium 
chloride, diSodium hydrogen phosphate (1.44 g) and (240 mg) of potassium dihydrogen 
phosphate into distilled water. The volume was brought up to one liter (1 L) and pH was 
adjusted to 7.4.  
2.1.2.7 Preparation of Lysis buffer 
Tris-HCL (50 mM) and EDTA (2 mM) were added into distilled water and brought up to 100 
ml, pH was adjusted to 7.4. 
 
2.1.3 Experimental animals 
Male Wister rats (250-300g) were obtained from the Biomedical Research Unit (BRU) of the 
University of Kwa-Zulu Natal (UKZN), Durban, SA and they were divided into six groups 
(n=7). The rats were given one week to acclimatize to their new environment before the study 
commenced. Temperature at (23-25℃), humidity (55-60%) and 12-hour day-light/dark cycle 
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throughout the study period were maintained. The rats were given ad libitum access to food 
and water and they were treated in humane manner following animal treatment guidelines 
provided by the Animal Research Ethics committee of the UKZN, Ethical clearance number: 
AREC /067/018M. 
2.1.4  Experimental design 
Groups I and IV were orally treated with 3.0 ml/ kg Body Weight (BW) of distilled water and 
100 mg/kg BW of naringenin in distilled water, respectively. Groups II, III, V and VI were 
made diabetic by a single intraperitoneal injection of 60 mg/kg BW streptozotocin and similarly 
treated with naringenin except group VI which was treated with insulin 2.0 U/kg BW (Table 
3). Three days after STZ injection, the rats were fasted overnight and the development of 
diabetes was confirmed using tail pick method to check blood glucose levels using the 
glucometer and glucometer strips. Rats with fasting blood glucose (FBG) of more than 11.0 
mmol/L were included in the study and those with FBG bellow were excluded from the study, 
the rats were fed and treated for a period of 56 days (Fig. 10). The animals were weighed every 
week and water intake was measured every day. 
On day 56 of the study glucose tolerance tests (GTT) were carried out by overnight fasting 
followed by intraperitoneal injection of D-glucose (3.0 g/kg BW) dissolved in 0.9% normal 
saline. Blood droplets mounted on glucometer strips were collected via tail pricks and then 
glucose levels measured at time intervals of 0, 30, 60, 90, and 120 minutes, by glucometer 
machine. Blood glucose time plots were done and the Area Under the Curve (AUC), expressed 
as AUC units [time (min)x blood glucose (mM)]. 
On day 57, the animals were euthanized by isoflurane overdose, blood samples were collected 
using cardiac puncture in heparinized tubes then separated into plasma and stored at -20˚C for 
further biochemical analysis. The hearts were quickly excised and washed in ice-cold 
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phosphate buffered saline (PBS). LVs were dissected and weighed. The tissues were snap 
frozen in liquid nitrogen and stored at -80℃ for further analysis (Fig. 10). The LV tissue 
homogenates were prepared by cutting (100 mg) of tissue and it was inserted into a 
microcentrifuge tube and 500 µl of lysis buffer was added and an electric homogeniser was 
used to homogenise the tissue, the tissue samples were immediately snap frozen in -80℃. 
 
 
Table 3. Animal treatment protocol 
(Group III received STZ treatment before naringenin treatment and group V received 


































 (2 U/kg BW) 
     I           X      
    II             X     
   III             X          X    
   IV                X     
    V            X X X  



















Figure 10. Schematic summary of methodology.  
 
2.1.5 Plasma insulin and HOMA IR 
Rat insulin (ELISA) assay was done by using the sandwich-ELISA principle to measure plasma 
insulin concentrations as per the manufacturer’s instructions. In a 96 well plate (100 µl) of the 
standard and samples was pipetted in triplicates in the wells and the plate was incubated for 90 
minutes at 37 ℃. The liquid in the wells was aspirated and (100 µl) of the biotinylated detection 
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working solution was added, the plate was incubated at 37 ℃ for one hour. The liquid was 
aspirated again and the plate was washed three times using (350 µl) wash buffer , the plate was 
blotted dry on absorbent paper, HRP conjugate working solution (100 µl) was added in the 
wells and incubated for 30 minutes at 37 ℃, the liquid was aspirated and the plate was washed 
5 times using the wash buffer. After the final wash (90 µl) of the substrate reagent was added 
and the plate was incubated for 15 minutes at 37 ℃. The reaction was stopped by the addition 
of (50 µl) stop solution and optical density (OD) was measured at 450 nm using the EZ 400 
microplate reader, fasting plasma insulin is expressed in (μ IU ml/L). 
Insulin resistance was calculated  using the Homeostasis Model Assessment of Insulin 




, where FPI: Fasting Plasma insulin (μ IU ml/L), and FBG: 
Fasting Blood Glucose (mM). 
 
2.1.6 Antioxidant Assays  
2.1.6.1 Catalase (CAT) Assay  
Catalase (CAT) is an antioxidant enzyme and it catalyses the detoxification of hydrogen 
peroxidase (H2O2) (a reactive oxygen species) forming water and oxygen molecule (Kaushal 
et al., 2018).  
                                                     
The CAT assay kit (Biocom Africa Diagnostics, SA) was used to measure the CAT activity in 
the tissue homogenate samples of the heart, following the manufacturer’s protocol. In this kit, 
(H2O2) reacts with ammonium molybdate used to stop the decomposition reaction above 
forming a yellowish complex used to calculate CAT activity using the measured OD. The kit 
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contained reagents such as: buffer solution (1.0 ml), substrate solution (0.1 ml), chromogenic 
agent (1.0 ml) and clarificant (0.1 ml) ,these reagents were pipetted in appropriate amounts into 
different tubes separated into control tubes and sample tubes containing the tissue homogenate 
samples, all the mixtures were incubated for 5 minutes at 37 ℃. Following the protocol, 
appropriate reagents were added continuously and the mixtures were incubated again for 1 
minute at 37 ℃. The tubes containing the mixtures were allowed to stand for 10 minutes at 
room temperature and OD was measured at 405 nm with 0.5 cm diameter cuvettes using the 
ThermoSpectronic spectrophotometer. Catalase activity (U/mgprot) was calculated using the following 
formula: CAT activity (U/mgprot) = (ODControl − ODSample) × (32.5 /1 × the volume of sample) × 
Dilution factor of sample before tested ÷ Protein concentration of tested sample (𝑚𝑔𝑝𝑟𝑜𝑡/𝑚𝐿). 
2.1.6.2 Superoxide Dismutase (SOD) Assay  
Superoxide Dismutase (SOD) catalyses the breakdown of superoxide (O2
-) radical into 
hydrogen peroxide (H2O2) or oxygen (O2) molecules (Indo et al., 2015). The activity of SOD 
was measured using the SOD assay kit (Biocom Africa Diagnostics, SA), following the 
manufacturers protocol. In the SOD assay kit superoxide ions are produced when xanthine and 
(O2) are converted into uric acid and (H2O2), this reaction is catalysed by xanthine oxidase 
(XOD). Tetrazolium salt is converted into formation dye by a superoxide anion, superoxide 
levels are reduced by the addition of SOD into the reaction, this decreases the levels of 
formazan dye formation. Therefore, in experiments SOD activity is measured as the inhibition 










In a 96 well plate (20 µl) of the sample (tissue homogenate) was pipetted into the appropriate 
sample wells. Distilled water (20 µl) was pipetted into the control and blank wells of the plate. 
Thereafter (20 µl) of the enzyme working solution, enzyme diluent and substrate application 
solutions were added into the appropriate sample and control wells following the 
manufacturer’s instructions. The mixtures were mixed fully and incubated at 37 ℃ for 20 
minutes. Thereafter the OD was measured at 450 nm using the EZ 400 microplate reader 
(Biochrom Ltd, Cambridge, UK). SOD activity (U/mg prot) was calculated using the formula provided 
in the kit: Inhibition ratio of SOD (%) = [(A Control-A Blank control) -(A Sample-A Blank sample)/ A 
Control-A Blank control] ×100%. SOD activity (U/mg prot) = Inhibition ratio of SOD (%) ÷ 50% × ( 
240 μL/20 μL ) × Dilution factor of sample before tested ÷ Protein concentration of sample (mgprot/mL) 
2.1.6.3 Glutathione Peroxide (GPx) Assay  
Glutathione peroxidase (GPx) is an antioxidant that catalyses the breakdown of hydrogen 
peroxide (H2O2). GSH-Px catalyses the reaction of (H2O2) and reduced glutathione (GSH) to 




The amount of GPx was measured using the GPx assay kit (Biocom Africa Diagnostics, SA) 
following the manufacturer’s instructions. Glutathione activity can be calculated by the 
consumption of reduced glutathione. The appropriate amount of tubes for the samples were 
used and they were separated into two groups of non-enzyme tubes and enzyme tubes, (0.2 ml) 
of 1 mmol/L GSH solution was added into the tubes containing the homogenate samples 
(enzyme tubes) and those without. These tubes were preheated at 37 ℃ in a water bath for 5 
minutes. Thereafter (0.1 ml) of the reagent application solution was added into the tubes. The 
tubes were heated in a 37℃-water bath again for another 5 minutes. An acid reagent (2.0 ml) 
was added at the end of the enzymatic reaction. The mixtures were centrifuged at 3100 g using 
the Z383k Hermle centrifuge for 10 minutes and (1.0 ml) of the supernatant was used to initiate 
the chromogenic reaction. Appropriate tubes were assembled according to the number of 
samples and the tubes were separated into blank tubes, standard tubes, non-enzyme tubes and 
enzyme tubes. GSH standard application solution (1.0 ml) was added into the appropriate tubes, 
(1.0 ml) of 20 µmol/L GSH standard solution was also added. The (1.0 ml) supernatant was 
added into the appropriate tube and (1.0 ml) of the application, solution was also added into 
the tubes. DTNB solution (0.25 ml) was added into all the tubes, (0.05 ml) salt reagent 
application solution was added at the end. The mixtures were allowed to stand for 15 minutes 
at room temperature, and the OD was measured at 412 nm using the ThermoSpectronic 
spectrophotometer. The GPx activity (nmol/mgprot) was calculated using the following 
formula: GSH − PX = (OD Non-enzyme tube-OD Enzyme tube)/ (OD Standard-OD Blank) × 
20 μmol/L × f2 × f ÷ (V × Cpr) where: f: dilution factor of sample before tested, f1: dilution 




2.1.6.4 Thiobarbituric Acid Reactive Substances (TBARS) Assay 
Thiobarbituric acid reactive substances assay was carried out in cardiac tissue homogenates as 
per the modified method previously described by Halliwell and Chrico in 1993 (Halliwell and 
Chirico, 1993; Adebiyi et al., 2016).  Left ventricular tissues (100 mg) were homogenised in 
(500 µl) of 0.2 % phosphoric acid. This homogenate mixture was centrifuged for 5 minutes at 
a temperature of 4℃ at 1600 g. Cardiac tissue supernatants (200 µL) were placed in new test 
tubes and (5 µl) of 2 % phosphoric acid, (400 µl) of 7 % phosphoric acid and (400 µl) of 
BHT/TBA solutions were added into the tubes as well. Hydrochloric acid 1.0 M (400 µl) was 
used to initiate the reaction and test tubes were then boiled at 100℃ in a water bath for 15 
minutes and the tubes were allowed to cool down at room temperature. n- butanol (1.5 ml) was 
then added into each test tube and mixed thoroughly and allowed to settle. Top phase (200 µl) 
was pipetted into a 96 well microplate in triplicates. The OD was measured at 532 nm and 600 
nm using the EZ 400 microplate reader. The concentrations MDA were calculated from the 
differences between the absorbances measured at 532 nm and 600 nm using an extinction 
coefficient of 1.56 x 105 cm-1M-1 and the MDA concentrations were expressed in 
(nmol/mgprot). 
2.1.7 Inflammatory cytokine tests 
2.1.7.1 Tumor Necrosis Factor Alpha (TNF- α) ELISA Assay 
Rat TNF-α (ELISA) kit using the sandwich-ELISA principle was used to determine the plasma 
TNF-α concentrations following the manufacturer’s protocol. In a 96 well plate (100 µl) of the 
standard and plasma samples was pipetted in triplicates in the wells and the plate was incubated 
for 90 minutes at 37 ℃. The liquid in the wells was aspirated and (100 µl) of the biotinylated 
detection working solution was added, the plate was incubated at 37 ℃ for one hour. The liquid 
was aspirated again and the plate was washed three times using (350 µl) wash buffer , the plate 
was blotted dry on absorbent paper, HRP conjugate working solution (100 µl) was added in 
36 
 
the wells and incubated for 30 minutes at 37 ℃, the liquid was aspirated and the plate was 
washed 5 times using the wash buffer. After the final wash (90 µl) of the substrate reagent was 
added and the plate was incubated for 15 minutes at 37 ℃. The reaction was stopped by the 
addition of (50 µl) stop solution, optical density (OD) was measured at 450 nm using the EZ 
400 microplate reader. TNF-α is expressed in pg/mL. 
2.1.8 Cardiac mass estimation  
LVs were dissected, weighed and the heart weight/body weight ratio (mg/g) and Left 
Ventricular Weight (LVW) /heart weight ratio (mg/g) were calculated. 
 
2.1.9 Statistical analysis  
Data was expressed as mean ± standard deviation. Unpaired t-tests with Welch’s correction or 
One-way ANOVA was used to determine statistical significance. GraphPad Prism® Software 
Version 8.0. (Graphpad Prism® Software, Inc. San Diego, CA, USA) was used to compare 







CHAPTER 3: RESULTS 
3.1 EVIDENCE OF DIABETES 
3.1.1 Weight gain 
The untreated diabetic group showed significantly (p < 0.0001) reduced weight gain compared 
to controls (Fig. 11). However, the naringenin or insulin treatment of diabetic rats significantly 
(p < 0.05) reduced weight loss compared to untreated diabetic group. Naringenin pre-treatment 
significantly (p < 0.05) showed improved body weights compared to naringenin post STZ 
treatment (Fig. 11). Naringenin treatment significantly (p < 0.0001) maintained a steady weight 
gain compared to controls. 
Figure 11. Changes in live body weights between days 0 and 57 of treatment (*, #p < 0.0001 
compared to control, ^, @ p < 0.05 compared to STZ group and &p < 0.05 compared to STZ+ 
NAR group).  
Normal control (NC), Naringenin (NAR), Streptozotocin (STZ), Streptozotocin+Naringenin 
(STZ+NAR),Naringenin+Streptozotocin+Narigenin(NAR+STZ+NAR), 
Steptozotocin+Insulin (STZ+INS). 
  * 
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3.1.2 Water intake  
Average daily water consumption per gram body weight was significantly (p < 0.0001) 
increased in the untreated diabetic group when compared to the controls. However, the 
naringenin or insulin treated groups showed a significantly (p < 0.05) decreased water 
consumption compared to untreated diabetic group (Fig. 12). Naringenin pre-treatment 
significantly (p < 0.05) showed reduced water intake compared to naringenin post STZ 
treatment (Fig. 12). 
 
Figure 12.  Average daily water intake per gram body weight in all treatment groups (****p < 
0.0001 compared to control group, @ p < 0.05 compared to STZ group and &p < 0.05 compared 
to STZ + NAR group). 
Normal control (NC), Naringenin (NAR), Streptozotocin (STZ), Streptozotocin+Naringenin 




3.1.3 Fasting blood glucose  
FBG concentrations were significantly (p < 0.05) elevated in the untreated diabetic group 
compared to the controls. Naringenin or insulin treatment significantly (p < 0.05) reduced FBG 
concentrations compared to untreated diabetic group (Fig. 13). Naringenin pre-treatment had 
no statistical significance when compared to naringenin post STZ treatment (Fig. 13). 
 
 Figure 13. Fasting blood glucose concentrations (***p <0.05 compared to control group, 
 # #, # # #p < 0.05 compared to STZ group). 
 
Normal control (NC), Naringenin (NAR), Streptozotocin (STZ), Streptozotocin+Naringenin 




3.1.4 Glucose tolerance test (GTT) & Calculated Area under the curve (AUC) 
The untreated diabetic rats presented with impaired glucose tolerance (Fig. 14 A). Calculated 
area under the curve (AUC) showed untreated diabetic rats significantly (p<0.0001) had more 
glucose intolerance compared to control (Fig. 14 B). Treatment with naringenin did not 
improve glucose intolerance. However, insulin treatment significantly (p < 0.05) improved it 
(Fig. 14 A & B). 
 
                      A                                                                                                 B 
 
Figure 14. Glucose tolerance tests (GTT) in various treatment groups. A) Blood glucose 
concentrations vs time (GTT curves) B) Calculated AUC from the GTT plots (****p < 0.0001 
compared to control group and # p < 0.05 compared to STZ group). 
Normal control (NC), Naringenin (NAR), Streptozotocin (STZ), Streptozotocin+Naringenin 




3.2 INSULIN RESISTANCE 
3.2.1 Fasting plasma insulin 
FPI concentrations were significantly (p<0.05) reduced in diabetic untreated group compared 
to the controls, while naringenin or insulin treatment significantly (p<0.05) improved FPI 
concentrations compared to untreated diabetic group (Fig. 15). Naringenin pre-treatment 
significantly (p< 0.05) improved FPI concentrations compared naringenin post STZ treatment 
(Fig.15). 
 
Figure 15. Fasting plasma insulin concentrations (****p < 0.05 compared to control group, 
@p < 0.05 compared to STZ group and 
&
p < 0.05 compared to STZ+ NAR group).  
Normal control (NC), Naringenin (NAR), Streptozotocin (STZ), Streptozotocin+Naringenin 




3.2.2 HOMA-IR  
Calculated HOMA-IR was significantly (p<0.0001) elevated in untreated diabetic group 
compared to controls (Fig. 16). However, naringenin or insulin treatment of diabetic groups 
significantly (p<0.05) decreased HOMA-IR values compared to untreated diabetic rats, 
respectively. Naringenin pre-treatment significantly (p < 0.05) reduced HOMA-IR compared 
to naringenin post STZ treatment (Fig. 16). 
 
Figure 16. Homeostasis Model Assessment (HOMA) of insulin resistance in all treatment 
groups (****p < 0.0001 compared to control group, @ p < 0.05 compared to STZ group and 
&p < 0.05 compared to STZ+ NAR group). 
Normal control (NC), Naringenin (NAR), Streptozotocin (STZ), Streptozotocin+Naringenin 




 3.3 ANTIOXIDANT STATUS 
3.3.1 Thiobarbituric Acid Reactive Substances (TBARS) 
Cardiac tissue MDA (marker of Lipid peroxidation) levels were significantly (P<0.05) 
increased in the untreated diabetic group compared to the control. Naringenin or insulin treated 
diabetic groups had significantly (p<0.05) decreased MDA concentrations compared to the 
untreated diabetic group. Naringenin pre-treatment significantly (p<0.0001) decreased MDA 
concentrations compared to naringenin post STZ treatment (Fig. 17). 
Figure 17. MDA concentrations were measured as an index of lipid peroxidation in all the 
treatment groups (****p < 0.05 compared to control, @p < 0.05 compared to STZ group and & 
p < 0.0001 compared to STZ+NAR group). 
Normal control (NC), Naringenin (NAR), Streptozotocin (STZ), Streptozotocin+Naringenin 




3.3.2 Catalase (CAT) activity 
Cardiac tissue catalase activity was significantly (p<0.05) reduced in the untreated diabetic 
group compared to the controls (Fig.18). However, naringenin or insulin treatment showed a 
significantly (p<0.0001) increased catalase activity compared to untreated diabetic rats. 
Naringenin pre-treatment significantly (p < 0.05) improved catalase activity compared to 
naringenin post STZ treatment (Fig. 18). 
 
Figure 18. Catalase activity in all treatment groups (#p < 0.05 compared to control group, @p 
< 0.0001 compared to STZ group and &p < 0.05 compared to STZ + NAR group). 
Normal control (NC), Naringenin (NAR), Streptozotocin (STZ), Streptozotocin+Naringenin 




3.3.3 Superoxide dismutase (SOD) activity 
Cardiac tissue SOD activity was significantly (p<0.05) decreased in the untreated diabetic 
group compared to the control group (Fig. 19). However, naringenin or insulin treatment 
significantly (p<0.05) increased SOD activity compared to untreated diabetic group. 
Naringenin pre-treatment significantly (p<0.05) improved SOD activity compared to 
naringenin post STZ treatment (Fig.19). Naringenin treatment of non-diabetic rats significantly 
(p < 0.05) increased SOD activity compared to controls. 
 
Figure 19. Superoxide dismutase (SOD) activity in all the treatment groups (**, # p < 0.05 
compared to control group, @p < 0.05 compared to STZ group and & p< 0.05 compared to STZ 
+ NAR group). 
Normal control (NC), Naringenin (NAR), Streptozotocin (STZ), Streptozotocin+Naringenin 




3.3.4 Glutathione peroxidase (GPx) activity 
Cardiac tissue glutathione peroxidase (GPx) levels significantly (p<0.0001) decreased in the 
untreated diabetic group compared to the control (Fig. 20). However, a significant (p<0.05) 
increase was observed in the naringenin or insulin treated groups compared to the untreated 
diabetic group. Naringenin pre- treatment significantly (p<0.0001) increased GPx activity 
compared to naringenin post STZ treatment group. Naringenin treatment also showed a 
significant (p<0.0001) increase in GPx activity when compared to control group (Fig. 20).  
Figure 20. Glutathione peroxide (GPx) activity in all the treatment groups (****, #p < 0.0001 
compared to control group, @ p < 0.05 compared to STZ group and &p < 0.0001 compared to 
STZ +NAR group). 
Normal control (NC), Naringenin (NAR), Streptozotocin (STZ), Streptozotocin+Naringenin 




3.4 INFLAMMATORY CYTOKINE LEVELS 
3.4.1 Tumor Necrosis Factor Alpha (TNF- α) activity 
Cardiac tissue TNF-α activity significantly (p<0.05) increased in the untreated diabetic group 
compared to the control. Naringenin or insulin treatment of diabetic rats significantly (p<0.05) 
decreased TNF-α compared to untreated diabetic rats. Naringenin pre-treatment significantly 
(p<0.05) decreased TNF-α activity compared to naringenin post STZ treatment (Fig.21). 
 
Figure 21. Tumor necrosis factor alpha (TNF-α) activity in all treatment groups (****p < 0.05 
compared to control group, # p< 0.05 compared to STZ and &p< 0.05 compared to STZ+NAR 
group). 
Normal control (NC), Naringenin (NAR), Streptozotocin (STZ), Streptozotocin+Naringenin 




3.5 Cardiac mass: Body mass ratio 
3.5.1 Heart weight/ Body weight ratio 
Untreated diabetic rats showed significant (p<0.05) increase in the HW/BW and LVW/HW 
ratios compared to the control group (Fig. 22 and 23). Naringenin or insulin treated diabetic 
groups showed a significant (p<0.05) decrease in the HW/BW and LVW/HW ratios compared 
to the untreated diabetic group, respectively. Naringenin pre-treatment significantly (p<0.05) 
decreased the HW/BW ratio compared to naringenin post STZ treatment (Fig.22).  
 
Figure 22. Calculated HW: BW ratio (****p < 0.05 compared to control group, 
#
p < 0.05 
compared to STZ group and 
&
p < 0.05 compared to STZ+NAR group). 
 
Normal control (NC), Naringenin (NAR), Streptozotocin (STZ), Streptozotocin+Naringenin 




3.5.2 Left ventricular weight/ Heart weight ratio  
 
Figure 23. Left ventricular weight to heart weight ratio (LVW/HW), (****p < 0.05 compared 
to control group, 
#
p < 0.05 compared to STZ group and &p<0.05 compared to STZ+NAR 
group). 
Normal control (NC), Naringenin (NAR), Streptozotocin (STZ), Streptozotocin+Naringenin 





CHAPTER 4: DISCUSSION OF RESULTS 
4.1 DISCUSSION 
Diabetes is a multifaceted metabolic disorder with characteristic changes of glucose 
metabolism resulting in increased production of ROS (Kapoor and Kakkar, 2014). Increased 
ROS causes an imbalance between oxidants and antioxidants. When antioxidants are depleted 
normal bodily functions are disrupted and vital body organs are damaged by exposure to ROS. 
Naringenin has been classified as a relatively harmless, safe and non-toxic substance, this is 
based on the classification of relative toxicity of chemicals (Surampalli e al., 2014). A study 
done on the preservation of intestine mucosal biochemical composition and cardiac muscle 
structure and function clarified naringenin as a safe drug (Surampalli et al.,2014, Deferme et 
al., 2008). These studies support the findings that suggest naringenin the naturally occurring 
substance has the potential to serve as a safe and novel pharmaceutical adjuvant.  
In this current study, we investigated whether naringenin treatment could mitigate some 
complications caused by myocardium exposure to hyperglycemia, using rat models of diabetes 
induced with STZ. Diabetes was induced by a single intraperitoneal injection of STZ (60 mg/kg 
BW), which caused a destruction to the pancreatic β-cells resulting into elevated hyperglycemia 
and hyperglycemia-induced oxidative stress (Nishigaki et al., 1989; Cheng et al., 2013).  
The untreated diabetic group exhibited significant weight loss when compared to the control 
(Fig. 11), type I diabetic patients normally lose weight regardless the food intake. Insulin 
deficiency prevents the body from getting glucose to supply the body with energy. As a 
compensatory mechanism the body utilizes stored fat and muscle energy causing a reduction 
in the overall body weight of the diabetic individual (McPherson and McEneny, 2012). 
Naringenin treatment attenuated weight loss by ameliorating lipolysis and proteolysis that is 
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increased in type I diabetic state. Naringenin pre-treatment improved weight loss compared to 
naringenin post STZ treatment suggesting that naringenin is a weight stabilizer (Shulman et 
al., 2011). Insulin treatment did not bring the animal weights to normal this could be due to 
insulin resistance resulting into glucose build-up forcing kidneys to remove the excess glucose 
through urine later resulting into weight loss (due to loss of calories) and dehydration.  
Naringenin treatment of non-diabetic rats showed a decrease in weight gain compared to 
control group both these groups had unlimited access to food and water. Naringenin treatment 
is known to prevent obesity and improve lipid levels in diabetic rats by inducing hepatic fatty 
acid oxidation, reducing lipid availability (especially triglycerides) allowing for the assembly 
and secretion of apolipoprotein B- containing lipoproteins, this leads to reduced hepatic lipid 
accumulation (Mulvihil and Huff, 2012). However, naringenin does not stimulate fatty acid 
oxidation in skeletal muscles instead it reduces lipid accumulation and promotes glucose 
uptake, it is also a weight stabilizer like metformin (Assini et al., 2015).  
The untreated diabetic group showed increased polydipsia compared to the control group (Fig. 
12). Diabetic patients have polydipsia due to hyperglycemia increasing osmotic pressure and 
diuresis leading to dehydration (Kraut and Madias, 2007). As a compensatory mechanism 
elevated osmolarity activates osmoreceptors which reduce antidiuretic hormone (ADH), which 
corrects the state of hyperosmolarity. If this compensatory mechanism fails, thirst is activated 
causing increased water intake. Naringenin treatment reversed polydipsia in the diabetic groups 
because there was reduced water consumption. Naringenin pre-treatment reversed polydipsia 
compared to naringenin post STZ treatment.  
Naringenin treatment improved fasting blood glucose compared to the untreated diabetic group 
we can thereby postulate that naringenin has an antihyperglycemic effect (Fig. 13), naringenin 
has previously been shown to reduce hepatic expression of the key gluconeogenic enzymes, 
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glucose-6-phosphatase (G6Pase) and phosphoenolpyruvate carboxykinase (PEPCK) which 
play a pivotal role in gluconeogenesis (Annadurai et al., 2012, Murunga et al., 2016). The 
untreated diabetic group showed elevated fasting blood glucose levels as expected for diabetic 
rats. Naringenin pre-treatment did not improve the fasting blood glucose levels compared to 
naringenin post STZ treatment this is due to insulin deficiency resulting into the inability of 
naringenin to affect blood glucose levels. 
Glucose tolerance tests were similar between the naringenin treated non-diabetic and control 
rats and so were the calculated AUC (Fig. 14). However, the untreated diabetic rats showed 
glucose intolerance when compared to the control. The calculated AUC also supported these 
results, since naringenin and insulin treatment were withheld on the day of GTT, it is therefore 
expected that glucose levels would not improve in both the naringenin and insulin treated 
groups. Naringenin pre-treatment did not have any effect on glucose tolerance compared to 
naringenin post treatment. The untreated diabetic rats showed glucose intolerance and the 
calculated AUC significantly supported these results (Fig. 14). 
The untreated diabetic rats showed lower levels of fasting plasma insulin and highly elevated 
HOMA-IR levels compared to controls (Fig. 15 and 16), HOMA-IR is a measure of IR and 
uses fasting plasma insulin levels and fasting blood glucose levels. High levels of fasting 
plasma insulin and increased resistance to insulin mediated glucose uptake are closely related, 
an increase in fasting plasma insulin levels is known to be a compensatory attempt to overcome 
the resistance to glucose uptake (Olefsky et al., 1973). Hence, the results show that the 
untreated diabetic rats have high levels of insulin resistance and the compensatory mechanism 
has failed to overcome the resistance of glucose uptake. STZ destroyed pancreatic β-cells but 
naringenin treatment improved their function by either regeneration or by reducing oxidative 
stress. Therefore, naringenin treatment significantly improved the fasting plasma insulin levels 
when compared to the untreated diabetic rats and the HOMA-IR levels were significantly 
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improved, showing improvement in the level of insulin resistance in the rats. Naringenin pre-
treatment significantly improved the fasting plasma insulin and HOMA-IR levels when 
compared to naringenin post treatment. 
Increased ROS leads to oxidative stress that causes lipid peroxidation leading to an 
overproduction of MDA, which is used as a biomarker of lipid peroxidation. MDA levels were 
significantly increased in the untreated diabetic rats compared to the control; these results were 
expected due to hyperglycemia-induced oxidative stress in the diabetic rats (Fig. 17). 
Naringenin treatment significantly decreased MDA levels compared to the untreated diabetic 
rats. These results suggest that naringenin treatment decreased lipid peroxidation by 
scavenging free radicals reducing oxidative stress (Song et al., 2018). Naringenin pre-treatment 
significantly reduces MDA levels compared to naringenin post-treatment.  
SOD, CAT and GPx antioxidants are known as first line defense antioxidants, they suppress or 
prevent the formation of free radicals or reactive oxygen species, low levels of these 
antioxidants show the presence of oxidative stress (Ighodaro and Akinloye,2018).  
CAT is a common antioxidant enzyme that uses iron or manganese as a cofactor and catalyzes 
the detoxication of harmful radicals into less harmful molecules. The untreated diabetic rats 
showed low levels of CAT activity when compared to control (Fig. 18), this suggests that there 
were high levels of oxidative stress which is expected for diabetic rats. Naringenin treatment 
significantly increased CAT levels compared to the untreated diabetic group, these results 
suggest that naringenin either scavenged free radicals causing reduced consumption of the 
antioxidants or naringenin could be binding free radicals resulting in less production of the 
antioxidant enzymes. Naringenin pre-treatment significantly improved CAT levels compared 
to naringenin post treatment. 
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SOD is an inducible antioxidant enzyme, it catalyzes the dismutation of harmful superoxide 
anions making less harmful substances. The untreated diabetic rats showed low levels of SOD 
when compared to control (Fig. 19). These results show that there were increased levels of 
oxidative stress, naringenin treatment significantly increased the SOD levels, showing that 
naringenin decreased free radicals or directly enhanced the production of antioxidants in the 
presence of free radicals. Naringenin treatment in the non-diabetic rats was also increased the 
antioxidant this could be because oxidative stress was completely reduced leading to an 
accumulation of the antioxidant enzyme SOD. Naringenin pre-treatment significantly 
increased SOD levels compared to naringenin post treatment. 
GPx is an inducible antioxidant enzyme that also plays a critical role in inhibiting the lipid 
peroxidation process reducing oxidative stress. The untreated diabetic rats showed significantly 
low levels of GPx compared to control (Fig. 20), these results show elevated levels of oxidative 
stress, which is expected in diabetic rats. Naringenin treatment significantly elevated GPx 
levels compared to the untreated diabetic rats, suggesting that naringenin could have reduced 
the levels of free radicals by enhancing the antioxidant levels or by binding the free radicals 
leading to reduced production of the enzyme. Non- diabetic naringenin treated group showed 
elevated levels of GPx activity compared to control, since GPx is an inducible antioxidant it 
gets used up when there are free radicals, so once the free radical levels are decreased pressure 
to detoxify them is reduced and this could resort to an accumulation of the excess GPx 
antioxidant. Naringenin pre-treatment significantly increased GPx levels compared to 
naringenin post treatment. 
Oxidative stress stimulates the production of pro-inflammatory cytokines such as TNF-α, 
which can be used as a biomarker of inflammation and/or oxidative stress (Chen et al., 2008). 
TNF-α injures endothelial cells resulting into endothelial dysfunction, inflammation and 
insulin resistance, it does this by damaging the mitochondrial chain complex III and this leads 
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to increased production of oxygen radicals inside the mitochondrion. TNF-α levels were highly 
elevated in the untreated diabetic rats compared to the control (Fig. 21), naringenin treatment 
significantly decreased TNF-α levels compared to untreated diabetic rats. The mechanism by 
which naringenin inhibits cytokine release is not limited to a specific stimulus, naringenin 
could have inhibited the activation of NF-kB and MAPK signaling pathways which are 
responsible for the development of inflammation or by scavenging free radicals reducing 
oxidative stress (Jin et al., 2017).  Naringenin pre-treatment significantly reduced TNF-α 
compared to naringenin post treatment. 
Left ventricular remodeling is characterized by inflammation or increased cardiomyocyte 
diameter/size (Wei et al., 2001; Adebiyi et al., 2016). Untreated diabetic rats showed 
significantly large heart weights compared to controls (Fig. 22 and 23), this could be due to 
constant hyperglycemia resulting in cardiomegaly. Cardiac mass was significantly reduced 
compared to control in the naringenin and insulin treated diabetic rats, this supports a study 
suggesting that naringenin retarded the development of left ventricular remodeling in diabetic 
rats by reducing MAPK and PKC levels responsible for cardiac remodeling and inflammation 
(Sabri et al., 1998; Adebiyi et al.,2016). Prior treatment of naringenin improved the cardiac 
inflammation and cardiac antioxidant levels of the diabetic rats, this supports the cardio-
protective ability of naringenin (Kamel et al., 2016). Naringenin treatment could have activated 
PPAR- α and PPAR-γ (PPARs are ligand-activated transcription factors that modulate several 
biological processes implicated in obesity, inflammation and metabolism of lipids and glucose) 
leading to the down regulation of NF-kB expression, responsible for hypertrophy (Zhang et al., 





CHAPTER 5: CONCLUSION 
5.1 CONCLUSION 
This study has shown that naringenin treatment has as an antidiabetic, anti-inflammatory and 
cardioprotective effect on the cardiac muscle this could be attributed to the ability of flavonoids 
to activate an antioxidant defense system by reducing ROS and increasing antioxidant levels. 
The findings support the claims of naringenin being a promising anti-diabetic plant extract that 
can be used to manage diabetes, mitigate diabetic conditions associated with cardiac 
complications. Prior treatment of naringenin before diabetes induction showed a great 
improvement in antioxidant, inflammatory cytokine levels and reduced cardiac mass, this 
supports the cardioprotective claims of naringenin. 
  
5.2 FUTURE STUDIES 
The study recommends future work using the same diabetic model and the same animal 
treatment protocol but the pre-treatment period of naringenin should be extended, to identify 
the potential ability of naringenin to prevent the onset of diabetes. Pathological studies 
particularly histology of the cardiac muscle will be included.  
 
5.3 STUDY LIMITATIONS 
In this study, pre-exposure time of naringenin treatment was limited, this could have had an 
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